Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma
Conditions
Interventions
Urelumab
Nivolumab
Locations
17
United States
Stanford University School Of Medicine
Palo Alto, California, United States
H. Lee Moffitt Cancer Center
Tampa, Florida, United States
University Of Chicago
Chicago, Illinois, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Lutherville, Maryland, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
September 29, 2014
Primary Completion Date
May 24, 2019
Completion Date
May 24, 2019
Last Updated
October 5, 2020
NCT07360314
NCT07539285
NCT07403721
NCT07524348
NCT03093116
NCT06898450
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions